TASK-1 (KCNK3) channels in the lung: from cell biology to clinical implications

Andrea Olschewski(Medical University of Graz), Alistair Mathie(University of Westminster), Bence Nagy(Medical University of Graz), Mélanie Lambert(Université Paris-Sud), Gábor Czirják(Semmelweis University), Emma L. Veale(Medway School of Pharmacy), Fabrice Antigny(Inserm), Péter Enyedi(Semmelweis University), Chandran Nagaraj(Medical University of Graz), Marc Humbert(Inserm), Grażyna Kwapiszewska(Cardio-Pulmonary Institute)
European Respiratory Journal
November 1, 2017
10.1183/13993003.00754-2017
Cited by 80

Related Papers

2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension
|European Heart Journal|2022|3.6k
Guide to Receptors and Channels (GRAC), 5th edition
|British Journal of Pharmacology|2011|1.9k
Benefits of omalizumab as add‐on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE
|Allergy|2004|1.1k
Pathologic assessment of vasculopathies in pulmonary hypertension
|Journal of the American College of Cardiology|2004|713
THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: G protein‐coupled receptors
|British Journal of Pharmacology|2019|712